Clinical Trial Update: Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase II open-label study evaluating HLX43, an anti-PD-L1 ADC, for advanced gastric or gastroesophageal junction adenocarcinoma; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• HLX43

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: RECRUITING